Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DNLI with free AI briefings, catalyst countdowns, and dilution alerts.

DNLI · Denali Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1B Cash on Hand
28.2mo Cash Runway
9.7% Short Interest
$35.82 Analyst Target (17)
Follow DNLI by email Get an email when DNLI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DNLI, unsubscribe in one click. Privacy

📣 What DNLI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tividenofusp Alfa
FDA approved Mar 2026 · Avlayah
Mucopolysaccharidosis II Phase 2/3 · NCT05371613 Active not recruiting
BIIB122 Parkinson Disease Phase 3 · NCT05418673 Terminated
DNL343 Amyotrophic Lateral Sclerosis Phase 2/3 · NCT05842941 Completed
DNL593 Frontotemporal Dementia Phase 1/2 · NCT05262023 Active not recruiting
Prophylactic Immunomodulatory (IM) Therapy Mucopolysaccharidosis Type IIIA Phase 1/2 · NCT06181136 Recruiting
DNL126 Mucopolysaccharidosis Type IIIA Phase 1/2 · NCT06181136 Recruiting
DNL151 Healthy Volunteers Phase 1 · NCT04557800 Completed
DNL201 Healthy Volunteers Phase 1 · NCT04551534 Completed
[14C] BIIB122 ([14C] DNL151) Healthy Volunteers Phase 1 · NCT05119790 Completed
DNL628 Alzheimer Disease, Early Onset Phase 1 · NCT07328451 Recruiting
DNL747 Amyotrophic Lateral Sclerosis Phase 1 · NCT03757351 Terminated
DNL919 Healthy Participant Phase 1 · NCT05450549 Completed
DNL921 Alzheimer's Disease Phase 1 · NCT07758595 Recruiting
DNL952 Late-onset Pompe Disease Phase 1 · NCT07354724 Recruiting
[14C]-DNL343 Healthy Volunteers Phase 1 · NCT06281158 Completed

Also used in these trials (approved or third-party drugs, not DNLI's own candidates): Idursulfase.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DNLI holds $1B in cash and short-term investments (as of Sep 30, 2026) and burns about $107.2M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DNLI files for a raise →

👥 Who Owns DNLI

Insiders 6.6% Institutions (418 holders) 93.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 19,634,011 12.25% 2026-09-30
Blackrock Inc. Institution (13F) 14,328,688 8.94% 2026-09-30
BAILLIE GIFFORD & CO Institution (13G, 5%+) 11,960,230 7.46% 2026-06-30
Temasek Holdings (Private) Ltd Institution (13F) 7,012,974 4.38% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 6,758,410 4.22% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 6,751,225 4.21% 2026-09-30
State Street Corporation Institution (13F) 6,682,013 4.17% 2026-09-30
FMR, LLC Institution (13F) 4,533,121 2.83% 2026-09-30
Geode Capital Management, LLC Institution (13F) 4,038,820 2.52% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 3,754,582 2.34% 2026-09-30
BAKER BROS. ADVISORS LP
Director · +26.10M options
Insider 3,422,366 2.14% 2026-06-03
Ryan J. Watts
President and CEO, Director · +257,249 options
Insider 2,417,217 1.51% 2026-08-12

Share count 160,290,546 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-04
filed 2026-09-09
Chin Peter Scott
Sale (S) 1,654 $22.29 204,538
2026-09-02
filed 2026-09-04
Thornberry Nancy
Sale (S) 615 $23.74 19,686
2026-09-02
filed 2026-09-04
Thornberry Nancy
Sale (S) 10,824 $22.85 20,301
2026-09-01
filed 2026-09-03
Schuth Alexander O.
Sale (S) 2,768 $23.44 278,995
2026-08-12
filed 2026-08-14
Watts Ryan J.
Gift (G) 32,220 – 2,120,384

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-04-05 Tividenofusp Alfa BLA +1.4% -6.2% -6.9%
2026-01-05 — BLA -8.8% -1.5% +5%
2025-12-04 — BLA +23.7% +5.8% -7.5%

Browse all historical PDUFA outcomes →

Get the full DNLI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DNLI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.